Nathan Vardi
Review via Scientific American
“Finding new therapies that target only cancer cells and did not kill healthy cells had become the holy grail of cancer drug development,” writes Nathan Vardi, a managing editor at MarketWatch and former editor at Forbes. For Blood and Money follows the path of one class of such products (“targeted small-molecule drugs” designed to fight blood cancers) that ultimately pits two biotech companies against each other in a race to market—and to an unimaginable payday. Readers are introduced to scientologists, restless entrepreneurs, clinical experts and the machinations of magnate financiers searching for the next billion-dollar blockbuster. In the middle of that friction of ambition and greed are the patients, desperate for cures and more time.
